Adaptive Biotechnologies expects full year 2023 revenue to be in the range of $205M to $215M. "We expect operating expenses, including cost of revenue, to be below full year 2022 operating expenses of $385.5M," company said.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on ADPT:
- Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2022 Financial Results
- Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2022 Financial Results on February 14, 2023
- Adaptive Biotechnologies initiated with an Outperform, $15 target at Scotiabank
- Adaptive Biotechnologies initiated with an Outperform at Scotiabank
- Adaptive Biotechnologies to Present at the 41st Annual J.P. Morgan Healthcare Conference
